Israel

Prothena

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Prothena Corporation Provides Update on Its Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease

Lead Product(s): Prasinezumab

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 22, 2020

Details:

The study did not achieve the primary goal, but did show signs of efficacy. Roche has begun further clinical development preparation and is reviewing the results from PASADENA Study Part 1.

Prothena

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson's Disease to be Presented at AAT-AD/PD

Lead Product(s): Prasinezumab

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 31, 2020

Details:

PASADENA is a two-part Phase 2 clinical study in patients with early Parkinson’s disease that is being conducted by Roche.

NeuroSense Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

NeuroSense Receives Orphan Drug Designation for Amyotrophic

Lead Product(s): Ciprofloxacin,Celecoxib

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 06, 2020

Details:

The clinical trials initiated in the United States and in Israel will evaluate safety, tolerability and efficacy of PrimeC, NeuroSense's product for ALS patients.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Prothena

Prothena Corporation Provides Update on Its Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease

Prothena

Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson's Disease to be Presented at AAT-AD/PD

NeuroSense Therapeutics

NeuroSense Receives Orphan Drug Designation for Amyotrophic